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Abstract
The accumulation of the amyloid-b peptide (Ab) into amyloid plaques, an essential event in Alzheimer’s disease (AD)
pathogenesis, has caused researchers to seek compounds that physiologically bind Ab and modulate its aggregation and
neurotoxicity. In order to develop new Ab-specific peptides for AD, a randomized 12-mer peptide library with Ab1-10 as the
target was used to identify peptides in the present study. After three rounds of selection, specific phages were screened,
and their binding affinities to Ab1-10 were found to be highly specific. Finally, a special peptide was synthesized according to
the sequences of the selected phages. In addition, the effects of the special peptide on Ab aggregation and Ab-mediated
neurotoxicity in vitro and in vivo were assessed. The results show that the special peptide not only inhibited the aggregation
of Ab into plaques, but it also alleviated Ab-induced PC12 cell viability and apoptosis at appropriate concentrations as
assessed by the cell counting kit-8 assay and propidium iodide staining. Moreover, the special peptide exhibited a
protective effect against Ab-induced learning and memory deficits in rats, as determined by the Morris water maze task. In
conclusion, we selected a peptide that specifically binds Ab1-10 and can modulate Ab aggregation and Ab-induced neuronal
damage. This opens up possibilities for the development of a novel therapeutic approach for the treatment of AD.
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Introduction
Alzheimer’s disease (AD) is a highly prevalent neurodegenera-
tive disorder and the leading cause of dementia in the elderly [1].
The characteristic symptoms of AD patients, including progressive
cognitive impairment, memory loss, and behavioral deficits, are
closely related to pathologic changes in the brain [2]. Senile
plaques, a key pathological feature of AD, are essentially
composed of the amyloid-beta (Ab) peptide. Ab is 39–43 residues
long and is generated by two successive proteolytic cleavages of the
amyloid precursor protein [3]. AD cases are thought to be chiefly
associated with the apparent failures in regulating Ab production
and clearance, leading to increased levels of Ab and consequent
neurotoxicity. Neurotoxic Ab is initially released as a monomer;
molecular interactions then cause it to aggregate into oligomers,
fibrils, and plaques in AD brains [4]. The most aggregation-prone
form, Ab1-42, which is the predominant and initial species
deposited in the brain parenchyma, is considered to be the major
pathogenic form in AD [5]. Oligomers are the most toxic Ab
species [6,7]. However, protofibrillar and fibrillar aggregates
including senile plaques are also toxic [8,9].
Although Ab aggregation leading to deposition is a critical event
in AD [10], the factors that affect Ab aggregation and accumulation
are not completely characterized. It is widely accepted that a
considerable number of environmental factors as well as some
intrinsic properties of Ab can work in concert to cause Ab
deposition and aggregation. These factors can influence the
thermodynamic stability of the various accessible conformations of
Ab that potentially cause AD. Recent evidence suggests that key
subdomains withinAb affectits propensity toward aggregation. The
N-terminal domain of Ab seems to play an important role in the
transition from soluble aggregates to insoluble plaques and acts as a
regulatorysite controlling both the solubilizationand disaggregation
process of the Ab molecule [11], especially the 10 N-terminal
residues of Ab [12]. Intriguingly, site-directed antibodies towards
the N-terminal residues 3–6 canrelieveamyloid burden in the brain
of an AD mouse model and improve their ability to perform
cognitive tasks [13]. Meanwhile, a few studies suggest that some
other regions of Ab also play important roles in aggregation,
including residues 17–20, 26–30, 30–35, and 39–41 [12,14,15,16].
In terms of therapeutic development, drugs locking these key
regions with high specificity can affect the dynamics of the entire Ab
molecule, preventing Ab self-aggregation and enabling the
resolubilization of previously formed aggregates.
Compounds that block Ab aggregation may ultimately be
clinically useful for treating AD [4,17]. Over the years, much effort
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inhibit the aggregation and toxicity of Ab. It is reported that
various compounds have inhibitory effects on the aggregation of
Ab, such as Ab antibodies [18], protease (b-o rc-secretase)
inhibitors [19], anti-inflammatory drugs [20], cinnamon extract
[21]. However, the stability, safety, validity, cost, and development
time limit the suitability of using these agents for different
purposes. Recently, peptide-based drugs are now viable alterna-
tives to biopharmaceuticals [22] and are comparable with
antibodies in some cases. As drug candidates, peptides have
several advantages over antibodies including lower manufacturing
costs, higher activity per mass, lower royalty stack, greater stability,
and a lower chance of unintended interactions with the immune
system [22].
A number of peptides have been designed to bind and inhibit
Ab based on the sequences and structures related to the self-
assembling property of Ab. Some of these peptides not only have
especially strong anti-Ab aggregation effects, but they can also
inhibit Ab neurotoxicity in vitro. More importantly, a few peptides
can also reduce cerebral amyloid deposition and attenuate AD-
type cognitive deterioration. For example, Austen et al. designed
peptide-based aggregation inhibitors containing the binding region
(residues 16–20) and retro-inversion of these sequences; these
peptides can also inhibit Ab neurotoxicity in vitro [23,24,25]. N-
methylation peptides of regions corresponding to the amyloid
self-recognition elements (e.g., residues 17–20) can prevent
Ab aggregation and inhibit Ab-induced toxicity in vitro
[26,27,28,29,30,31,32]. Moreover, two N-methylation peptides
can reverse the Ab-induced inhibition of long-term potentiation at
remarkably low stoichiometry [32]. Nevertheless, there may be
some potential limitations associated with some of these peptide
therapies, including insolubility and toxicity [32]. The various b-
sheet breaker peptides and the amyloid sequence-derived
pentapeptide LPYFDa effectively inhibit fibrillogenesis and the
subsequent deposition of amyloids both in vitro and in vivo;
furthermore, they can improve behavior in AD model animals
[33,34,35,36,37]. D-amino acid peptides attenuate Ab aggregation
and cell toxicity, and reduce amyloid plaque load in transgenic
mice [38,39,40]. Although the high dose necessary to observe
these effects may preclude their use as a preventive or therapeutic
drug [39], they may be suitable for use as probes for detecting
amyloid plaques in living brains [38]. However, despite these
promising results, very few aggregation inhibitors have reached
clinical trials.
Phage display technology is a powerful method for identifying
peptides that can target any type of biomolecule [41]. It is a
technique in which bacteriophages are engineered to insert a
foreign DNA fragment with their capsid proteins and hence
express a peptide on their external surfaces. The peptides selected
by this method tend to be directed toward biologically relevant
sites on the surface of the target protein. Consequently, peptides
derived from library screenings often modulate the target protein’s
activity both in vitro and in vivo and can be used as lead
compounds in drug design as well as alternatives to antibodies for
target validation in drug discovery [42]. Recently, 20- and 12-mer
peptides were used to screen peptides specific to variable lengths or
forms of Ab [12,38,43,44].
As potential therapeutic agents, peptides that directly bind to
Ab are still highly desirable. Although phage display with Ab1-10
as the target to find such peptides is not reported, we reasoned
that this method might yield Ab1-10-specific peptides. Here,
we successfully identified such a peptide and investigated its
properties.
Materials and Methods
Biopanning of M13 phage display library against Ab1-10
A randomized 12-mer peptide library presented on M13 phages
(PhD-C7C; New England Biolabs, USA) was used for screening
against Ab1-10 (Xi’an Huachen Biotechnology, China). The well of
an ELISA plate (Shanghai Go On Chemical Ltd., China) was
coated with a 100-ml aliquot of 100 mg/ml streptavidin (Sigma,
USA) and 0.1 mol/l NaHCO3 (pH 8.6) overnight at 4uC. A 10-ml
aliquot of 2.0610
13 phage units of purified phage from the initial
library with 100 mg/ml biotin-Ab1-10 (Xi’an Huachen Biotechnol-
ogy, China) was solubilized in 400 ml phosphate-buffered saline
(PBS) with 0.05% Tween-20 (PBST, pH 7.4). The mixed solution
was subsequently incubated for 60 min at 37uC and overnight at
4uC to allow complete binding between phages and Ab1-10. The
next day, the solution in the ELISA plate was discarded, and the
mixed solution was added to the well for 60 min. The well was
washed 5 times with PBST followed by 5 washes with glycine–HCl
in order to eliminate the non-specific bound phages. Then, 0.1
mmol/l NHS–LC–Biotin (Sigma, USA) was added to the well and
incubated with agitation for 10 min twice. Next, phages bound to
the target were eluted with 0.2 mol/l glycine–HCl buffer (pH 2.2)
with 0.1% bovine serum albumin (Sigma, USA). After 10 min, the
solution was neutralized with 15 ml 1 M Tris–HCl buffer (pH 9.1).
After the round of biopanning, logarithmically growing
Escherichia coli (ER2738 host strain; New England Biolabs, USA)
was infected with a portion of the eluted phages. After
amplification, the bacteria were removed by centrifugation, and
the phages were purified by serial precipitation with a 20% PEG-
8000/2.5 M NaCl solution overnight at 4uC. The phage pellet
obtained by centrifugation was finally solubilized in TBS (50 mM
Tris-HCl and 150 mM NaCl) supplemented with 0.02% NaN3.
The titers of eluted phages were determined by serial dilution
after the round of biopanning. Amplification was determined by
counting the blue plaques obtained after E. coli infection and
culturing on a selective medium containing isopropyl-beta-d-
thiogalactoside (ICN; Biomedical, Belgium) and 5-bromo-4-
chloro-3-indolyl-beta-d-galactopyranoside (Sigma, USA). The
remaining phages were grown in bacterial culture overnight,
pack-aggregated, expressed through co-infection with a helper
phage, and precipitated from the bacterial supernatant. The
precipitated phages were then used for subsequent rounds of
panning until an obvious enrichment phenomenon appeared.
Assay to determine the affinity of the selected phages for
Ab1-10
Real-time biomolecular interaction analysis (BIA; Amersham
Pharmacia, USA) based on surface plasmon resonance was used to
assess the affinity of the interaction between the selected phages
and Ab1-10. In the binding specificity test, 100 mg/ml streptavidin
and 0.1 mmol/l biotin were immobilized in flow cell 1, and
100 mg/ml streptavidin and 100 mg/ml biotin-Ab1-10 in flow cell
2, by amine coupling onto the carboxylated dextran layer of a
CM5 chip. The screened phage (1.0610
11 phage units) was then
injected over flow cells 1 and 2 at 5 ml/min for 6 min. The
interaction was monitored as a change in the SPR signal. Greater
differences in the response signals (RU) between cells 2 and 1
indicate higher affinity. The procedure of the competitive
inhibition test was similar to that of the binding specificity test,
except that the selected phage pre-combined with Ab1-10 was
injected. BIA evaluation 3.2 software was used to assume one-to-
one binding. For the Biacore experiments, samples were run in
duplicate, with HBS-EP (5 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA, and 0.005% surfactant P20 (pH 7.4) as the running buffer.
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and deactivated, and used as a reference. The response from the
reference surface was subtracted from all curves when evaluating
the results.
Sequencing of selected phage clones and synthesis of
the special peptide
Phage single-stranded DNA was isolated using phenol/chloro-
form extraction [45]. The phage genome was sequenced using the
Sanger method with two sequencing primers: 5-
HOGTA TGG
GAT TTT GCT AAACAA C-3 and 5-
HOCCC TCA TAG TTA
GCG TAA CG-3 (New England Biolabs, USA). The DNA
sequence was analyzed on a CEQ 2000 XL DNA Analysis System
(Beckman-Coulter, Belgium). The sequence was read automati-
cally using the JaMBW 1.1 software.
The optimal monoclone phage displaying sequence was selected
and synthesized by Xi’an Huachen Biotechnology Company,
using standard solid-phase peptide synthesis. All peptides were
purified and characterized by MALDI-TOF mass spectrometry.
Morphological changes in Ab1-42 aggregation under
various conditions
Ab1-42 was dissolved in sterile filtered H2O at 1.0 mg/ml and
was immediately diluted to 0.5 mg/ml (115 mM) in PBS with or
without an equimolar concentration of the special peptide or
selected phage (1.0610
11 phage units), Ab1-10,o rA b1-42 alone as a
control. Aggregation was allowed to progress in an incubator for 7
days at 37uC. Electron micrographs were taken using a JEOL
100CX transmission electron microscope with uranyl acetate
negative staining.
Cell toxicity assay
Ab1-42 was dissolved in sterile filtered H2O at 100 mM. The
solution was incubated in an incubator at 37uC for 7 days, so that
Ab would go into the ‘‘aggregated phase,’’ and stored at 4uC
before use. Low-differentiated PC12 cells (Cell Bank, China) were
maintained in logarithmic-phase growth on poly-l-lysine-pre-
coated (Sigma, USA) 100-mm dishes (Corning, USA) in DMEM
(Gibco, USA) containing 10% fetal bovine serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin. Cultures were incubated
at 37uC in a 5% CO2 humidified atmosphere.
Different concentrations of aggregated Ab1-42 were tested to
assess its effect on neuronal cell viability. After PC12 cells were
incubated with Ab1-42 (0 (control), 0.01, 0.1, 1, 10, and 20 mM) for
24 h, cell viability was measured using cell counting kit-8 (CCK-8;
Beyotime Institute of Biotechnology, China).
To evaluate the role of the special peptide in Ab1-42-mediated
neurotoxicity, PC12 cells were incubated in the presence of 20 mM
Ab1-42 together with several final concentrations of the special
peptide (0.0004, 0.004, 0.02, 0.1, 0.5, and 2.5 mg/ml) for 24 h. To
investigate whether the observed effects were due to the special
peptide, PC12 cells were treated with the same final concentra-
tions of the special peptide alone for 24 h and cell viability was
subsequently evaluated.
The CCK-8 kit was used to count living cells. Briefly, 10 mlo f
the kit reagent was added to the cells treated as described above in
96-well plates and incubated for 3 h. Cell viability was assessed
using the ELISA plate reader at 450 nm.
Apoptosis assessment with propidium iodide staining
Propidium iodide (PI) staining was performed to evaluate the
status of apoptosis as follows. PC12 cells were incubated for 24 h
with any one of the following three treatments: (1) without the
special peptide or aggregated Ab1-42 as a control, (2) with 20 mM
Ab1-42 only, and (3) with both 20 mMA b1-42 and the special
peptide at concentrations of 0.0004, 0.004, 0.02, 0.1, 0.5, and
2.5 mg/ml. All samples were centrifuged for 10 min at 8006g, and
the supernatants were discarded. After washing twice with PBS,
the supernatants were fixed in 70% ethanol (100 ml) overnight at –
20uC. The cells were then centrifuged for 10 min at 1,2006g,
washed twice with PBS, and stained with the DNA-specific
fluorochrome propidium iodide (PI; Sigma, USA) at a terminal
concentration of 50 mg/ml. The mixed cells were then filtered and
incubated in the dark at 4uC for 30 min before flow cytometric
analysis (Beckman-Coulter, USA). A total of 1,000 cells were
counted to determine the percentage of cells exhibiting the
morphological hallmarks of apoptosis such as DNA fragmentation,
nuclear condensation, or segmentation.
Animals, surgery, and drug administration
Ethics statement: this study was approved by the Committee on
the Ethics of Animal Experiments of Anhui Medical University
(Permit Number: 12-2866). All animal procedures were carried out
in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health. All surgery was performed under chloral hydrate, and
all efforts were made to minimize suffering.
Forty experimentally naive male Sprague–Dawley rats (SD;
Beijing Vital River Experimental Animal Technology, China),
weighing 260–280 g at the beginning of the experiment were used.
They were housed individually in a room maintained at 23uC with
a 12-h light–dark cycle (lights on at 08:00 h) for the duration of the
experiment. Rats were allowed free access to food and water
except during experimental testing. Rats anesthetized with chloral
hydrate (350 mg/kg, i.p.) were positioned in a stereotaxic
instrument (RWD Life Science, China), and a cannula (RWD
Life Science, China) was implanted into the left cerebral ventricle
(A: 0.3 mm, L: 1.2 mm, V: 3.6). Rats were allowed 5 days of
recovery after the surgery. The correct location of the cannula was
checked by dissecting the brain following the completion of the
experiments. Only animals with correctly placed cannulas were
used in the evaluation of the experiments. Six rats in each group
were used for the final analysis. The special peptide was dissolved
in 0.9% saline solution before use. Ab1-42 (Sigma, USA) was also
dissolved in 0.9% saline solution. The solution was then incubated
at 37uC for 7 days to induce formation of aggregated Ab and
stored at 4uC before use. For intracerebroventricular administra-
tion in vivo, aggregated Ab1-42, the special peptide binding to the
Ab1-10, or saline solution was infused with the aid of a mini-pump
(RWD Life Science, China). The rats were randomly divided into
three groups. (1) AD model group: the AD model rats were
established as described previously [46]. After surgery, the rats
were injected with 3 ml aggregated Ab1-42 (1 mg/ml, 0.8 ml/min) on
days 5, 8, and 11, and with 3 ml saline solution (0.6 ml/min) on the
other days, days 5–14 (2) The special peptide treatment group with
three subgroups: AD model rats were infused daily with 3 ml
special peptide at different final concentrations (0.110, 0.522, and
2.610 mg/ml at 0.6 ml/min) for 14 consecutive days from day 5
onwards. (3) Control group: the rats were infused daily with 3 ml
saline solution (0.6 ml/min) alone throughout the same period.
Upon completion of behavioral testing, the rats were sacrificed by
decapitation.
Morris water maze task
The apparatus and procedure were slightly modified as
described previously [47]. Briefly, the water maze apparatus
consisted of a circular pool 150 cm in diameter, 60 cm deep, and
A Peptide Binds to b-Amyloid
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A black escape platform (10 cm diameter, 24 cm height) was
placed in one of the 4 quadrants of the pool (in target quadrant 2)
and submerged approximately 1.5 cm below the water surface.
Each rat’s swimming performance was monitored by a video
camera linked to a computer-based image analyzer (Chinese
Academy of Medical Sciences, China). Place learning was tested
for 10 consecutive days. Each rat was trained to find the platform
with 4 successive trials a day. The sequence of water-entering
points differed each day, but the location of the platform was
constant. The time taken to find the platform (escape latency),
swimming speed, and the distance traveled were measured and
averaged over 4 trials. If a rat failed to find the platform within
60 s, it was placed on the platform manually; regardless of
whether the rat found the platform, it was kept there for 30 s.
Each animal was subsequently returned to its cage until the next
trial. After all of the rats completed 1 trial, the next trial began
and followed the same order of rats. On day 10 of training, an
additional trial was given as a probe trial by removing the
platform. The animals were placed in the quadrant where the
platform was previously located in the fourth starting position and
were put through a single test-free swimming period for 60 s. The
percentage of distance and time spent in the quadrant where the
platform was previously located (target quadrant) were used as
measures of spatial memory.
Statistical analysis
The data followed a normal distribution, and are presented as
the mean 6 standard error of the mean (SEM). For the place
learning test in the Morris water maze task (MWM task), analysis
was performed using a two-way repeated-measures analysis of
variance (ANOVA) with day and treatment as independent
variables. For the other tests, statistical analysis was performed
using ANOVA with groups as the independent variable. Post-
hoc analysis using Tukey test was used to compare results for
different days and groups. Statistical significance was set at
P,0.05.
Results
Selection of specific phages binding to Ab1-10
After three rounds of screening, the eluted phage titers
progressively increased after each round of panning (Ps,0.01),
suggesting that non-specific phages were eluted and specific phages
were amplified.
Affinity of Ab1-10 for the selected phages
In the binding specificity test, as reaction time increased, the
positive difference of RU between flow cells 2 and 1 gradually
increased (Fig. 1A), indicating that the combined power of the
selected phages and streptavidin–biotin–Ab1-10 was significantly
stronger than that of the selected phages and streptavidin–biotin.
This result suggests that high binding specificity and affinity exist
between the selected phages and Ab1-10. In the competitive inhibition
test, as reaction time increased, the positive difference in RU between
flow cells 2 and 1 also gradually increased (Fig. 1A). This result
indicates that the bonding force between the selected phages pre-
combined with Ab1-10 and streptavidin–biotin–Ab1-10 in cell 2 was
also higher than that between the selected phages and streptavidin–
biotin in flow cell 1. However, the positive difference between cells 2
and 1 in the competitive inhibition test was lower than that in the
binding specificity test for all corresponding time points; this is
because the binding site of the selected phages is partly locked by the
pre-combined Ab1-10. Together, the results suggest that the affinity
between the selected phages and Ab1-10 is highly specific.
Sequencing of the selected phage clones and synthesis
of the special peptide
The DNA of the 20 clones selected on the basis of their affinity
for Ab1-10wassequenced (Fig.1B).The librarywas enriched inthree
sequences: PYRWQLWWHNWS, TLAHPYH, and SSSPSKH.
Since the 12-mer peptide library was used for screening against Ab1-
10, TLAHPYH and SSSPSKH were regarded as contaminants of
the other sequences selected in our experiment. The target clone
possessed a peptide, PYRWQLWWHNWS, which was then used to
synthesize the special peptide.
Figure 1. The specific affinity and amino acid sequences of the selected phages. (A) Specific affinity between Ab1-10 and the phages
screened for three rounds. Real dark line: binding specificity test of the screened phages; Dash line: competitive inhibition test of the small peptide;
Horizon line: the baseline of reaction unit; (B) Amino acid sequence of peptides displayed by the 20 selected phage clones. Frequency of peptides
was displayed by the phage clones. Three sequences were highly represented.
doi:10.1371/journal.pone.0027649.g001
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various conditions
Some obvious plaques were observed for Ab1-42 or Ab1-10 alone.
However, after the addition of the selected phages or the special
synthetic peptide, the plaques were instead of bundles of short
fibrils. This indicates that the selected phages and special synthetic
peptide can inhibit the aggregation of Ab1-42 into plaques (Fig. 2A).
Effects of the special peptide on Ab1-42-mediated
neurotoxicity in vitro
As shown in Fig. 2B, the viability of cells treated with Ab1-42 only
at concentrations .0.01 mM was significantly decreased in a
concentration-dependent manner (Ps,0.05). Based on these results,
a final concentration of 20 mMA b1-42 was selected as the optimal
concentration for subsequent experiments because cell viability was
about60%atthatconcentration.Inaddition,celldeathwith 20 mM
Ab1-42 appeared to be mainly due to apoptosis (Fig. 2D).
To investigate the effect of the special peptide on Ab1-42-
medidated neurotoxicity, PC12 cells were incubated in the presence
of 20 mMA b1-42 together with several concentrations of the special
peptide. Compared with the control, cell viability was significantly
decreased with 20 mMA b1-42 treatment (P,0.01). In the treatment
groups, the pattern of cell viability exhibited an inverted ‘‘U’’ shape.
The intermediate concentrations (i.e., 0.004, 0.02, 0.1, and 0.5 mg/
ml) of the special peptide significantly increased cell viability
(Ps,0.05), while smaller (0.0004 mg/ml) and larger doses (2.5 mg/
ml) were ineffective (Ps.0.05) (Fig. 2C). This neuroprotective effect
of the special peptide on Ab1-42-induced cell death resulted
completely from the net action of the special peptide on Ab1-42
aggregation, because the viabilities of PC12 cells incubated with
different concentrations of the special peptide alone were similar to
those of the control group (data not shown).
PI staining revealed that the percentage of apoptotic cells
among groups exhibited a ‘‘U’’ shape; i.e., the percentage of
apoptotic cells was significantly higher in the presence of 20 mM
Figure 2. The special peptide alleviates Ab aggregation and toxic effects in vitro. (A) Electron microscopic analysis of morphological change
showing the effect of the special peptide or selected phage on Ab1-42 aggregation. Ab1-42 (a) or Ab1-10 (c) alone was incubated for 7 days; Ab1-42 with
special peptide (b) or the selected phage (d) was incubated for 7 days; (B) Different concentrations of aggregated Ab1-42 were tested to assess its
effect on neuronal cell viability by CCK-8 assay. *P,0.05 when compared with the control group; (C) Cell viability was assessed in the presence of
20 mMA b1-42 and different concentrations of the special peptide by CCK-8 assay. *P,0.05 when compared with the control group.
#P,0.05 when
compared with the group treated with 20 mMA b1-42 only (note: 0.04 mg/ml peptide equal to 20 mM); (D) Detection of apoptosis in PC12 cells by PI
staining. *P,0.01 when compared with the control group.
#P,0.01 when compared with the group treated with 20 mMA b1-42 only.
doi:10.1371/journal.pone.0027649.g002
A Peptide Binds to b-Amyloid
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27649Ab1-42 than that of the control (P,0.05). Furthermore, the
increase was markedly attenuated by combined treatment with
several concentrations of the special peptide (i.e., 0.004, 0.02, 0.1,
and 0.5 mg/ml) (Ps,0.05), but it was not significantly different from
these doses (Ps.0.05) (Fig. 2D).
Performance in the MWM test
Fig. 33 shows the performance of rats in finding the hidden
platform in the MWM task. The latency progressively decreased
with days for all rats combined (F(9,225) =91.49, P,0.01; Fig. 3A),
suggesting that the rats were able to learn the task. The repeated-
measures ANOVA indicates that the effect of treatment on the
latency was significant (F(4,25) =3.121, P=0.0324). Post-hoc
analysis shows that the latency in the AD model rats was longer
than that in the control rats (P=0.041). However, among the three
special peptide-treated groups, only the latency of the 0.522 mg/ml
group was significantly shorter than that of the AD model group
(P=0.047), and was similar to that of the control group.
The cumulative distance also declined daily (F(9,225) =78.09,
P,0.01; Fig. 3B). The repeated-measures ANOVA indicates that
treatmenthadsignificanteffectonthecumulativedistance(F(4,25) =
4.941, P=0.005). The AD model rats swam significantly longer
distances than the control rats (P=0.021); only the 0.522 mg/ml
special peptide-treated group had a shorter latency than the AD
model group (P=0.029). The results of the latency and distance
suggest that repeated daily infusion of the special peptide at
0.522 mg/ml significantly ameliorates the impairment of perfor-
mance caused by Ab1-42. Swimming speed was similar among
groups (F(4,25) =0.897, P=0.467; Fig. 3C), indicating that the
cognitive performance observed under the various treatments is not
due to potential alterations of locomotor function.
In the probe trial test, the percentage of time in the target
quadrant showed significant effect of treatment (F(4,25) =7.984,
P,0.01; Fig. 3D). This indicates that the AD model rats searched
the target quadrant for a significantly less time than the control
rats (P,0.001); only the 0.522 mg/ml special peptide-treated rats
spent significantly more time than the AD model rats (P=0.025).
The percentages of cumulative distance in each group of rats
corresponded with the percentages of escape latency (data not
shown).
Discussion
Using phage display technology, we identified a peptide that
binds specifically to Ab1-10. Meanwhile, the special peptide
inhibited the aggregation of Ab1-42 into plaques, and reduced
Figure 3. Performance of the rats in the Morris water maze. (A) latency, (B) distance and (C) swimming speed in the place learning test; (D) the
percentage of time spent in the target quadrant in the probe trial.
#P,0.05 when compared with the model group. (note: the 0.522 mg/ml special
peptide equimolar to Ab1-42).
doi:10.1371/journal.pone.0027649.g003
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concentrations. Moreover, the special peptide exhibited a
protective effect against Ab1-42-induced learning and memory
deficits in the MWM task.
Based on previous studies, we reasoned that a peptide could be
selected by phage display technology using Ab1-10 as the target.
After three rounds of screening, the phages were selected. The
affinity between the selected phages and Ab1-10 was assessed by
BIA; the results show that the affinity between them was highly
specific. Meanwhile, we found that this method is suitable for
identifying positive correlations between selected phages and
peptides; it is superior to the orthodox ELISA because it maintains
the natural properties of biomolecules without the need for
fluorescent and isotope labeling, therefore making the results more
reliable. Three amino acid sequences were identified; the sequence
of one was interesting, while the others were considered to be
contaminants. We chose to use this target sequence to synthesize
the special peptide.
The presence of the selected phages or special peptide elicited
dramatic morphological features in that some observed plaques
were instead of bundles of fibrils. This suggests that specific phages
and the special peptide could inhibit Ab aggregation into plaques.
Although this method led to fibril formation, which is considered
to be an aggregation pathway originating from a high entropic
barrier and a thermodynamically unfavorable event, a recent
study indicates that the equilibrium between toxic and non-toxic
Ab intermediates exhibits a dynamic nature [48]. Furthermore,
the non-aggregated and aggregated states of Ab are in equilibri-
um, and soluble forms are more accessible to clearance and
degradation than insoluble forms [49]. In this study, the special
peptide was able to disaggregate plaques due to steady-state
equilibrium between Ab in plaques and in the monomeric form
[50]. This ultimately led to increased amounts of monomeric Ab,
which is more easily cleared from the brain [51] and can play a
neuroprotective role in the brain [52].
Extracellular Ab peptides are highly cytotoxic to neuronal cells,
and the underlying mechanisms may include free radical damage,
oxidative stress, and mitochondrial dysfunction of neurons,
which ultimately induce apoptosis [2]. Through interactions with
unidentified targets on the cell surface, Ab initiates a cascade of
intracellular events that culminate in neuronal death. Recent
studies show that the dying cells exhibit apoptotic characteristics in
AD brains and cultures of primary neurons and neuronal cell lines
exposed to Ab [53,54]. Furthermore, apoptosis in neurons may be
responsible for neuronal death in AD [55]. Applying Ab to
cultured cells even at micromolar concentrations can cause
apoptosis [56]. PC12 cells were used in this study as a neuronal
model because they biochemically and morphologically resemble
neurons after differentiation and are particularly sensitive to Ab
peptides [57]. Moreover, they are relatively easy to culture and
survive longer than primary cultured neurons [58]. We found that
Ab-induced cell death was attenuated by the addition of the
special peptide at 0.004, 0.02, 0.1, and 0.5 mg/ml. Meanwhile, the
percentage of apoptotic cells was markedly reduced by combined
treatment with the special peptide (i.e., 0.004, 0.02, 0.1, and
0.5 mg/ml). The positive effect of the special peptide was
significant at a molar ratio of peptide: Ab ranging from 0.1 to
12.5. Interestingly, the relationship between changes in concen-
tration and efficacy of the special peptide in these experiments met
the pattern of inverted U-shaped dose-effect curve (IUSDEC). The
IUSDEC is widely described and poorly understood phenomenon
in the pharmacological field. The basic concept is that, the effects
of increasing dosages of a given compound appear to increase up
to a maximum, and then the effects decrease [59]. A recent
comprehensive review has exhibited many examples of such
curves in pharmacology, such as cardiac glycosides, anti-tumor
drugs and drugs of central nervous system, chemoprevention of
stroke, traumatic brain injuries [60]. Similarly, it is difficult to
elucidate the mechanisms underlying the IUSDEC in our study.
We speculated that the lower concentration of the special peptide
might be too low to interfere sufficiently the interaction between
the special peptide and Ab, so that the protective effect could not
be produced. On the other hand, the reduced effect at the higher
concentration of the special peptide might be due to that it
stimulates the body to generate endogenous Ab or enhances the
toxic process of Ab, or produces self-cytotoxicity. For the latter,
however, our unpublished data had suggested that the special
peptide had no cytotoxicity for PC12 cells, even up to a
concentration of 2.5 mg/ml.
An animal AD model induced by intracerebroventricular Ab
infusion is particularly attractive for evaluating drugs for AD.
Ample experimental evidence indicates that single or chronic
intracerebroventricular administration of several kinds of Ab
peptides (i.e., Ab25-35,A b1-40, and Ab1-42) can induce cognitive
impairment [61,62,63,64]. Although the effects of Ab on learning
and memory have been extensively studied, the mechanism by
which Ab causes cognitive deficits is not clearly understood. A
recent study suggests that the spatial learning and memory deficits
induced by Ab peptides in rodents may not be entirely related to
Ab-induced neuronal damage such as the activation of glial cells,
and neuroinflammatory and oxidative responses [65]. And it is
also indicated that Ab1-42-induced mitochondrial mislocalization
contributes to late-onset behavioral deficits in a transgenic
Drosophila model [66]. According to the validated in vitro
concentrations of the special peptide, we chose three in vivo doses
(i.e., 0.110, 0.552, and 2.610 mg/ml); the corresponding molar
ratios of peptide: Ab were 1, 5, and 25, respectively. The results
showed that Ab1–42 injection into the lateral ventricle induced
spatial learning and memory impairment, and infusing the special
peptide alone at 0.552 mg/ml significantly ameliorated impairment
in the MWM. The beneficial effect of the special peptide on
learning and memory may be related to its activity as a direct
binder to Ab1–10. Further studies are needed to fully understand
the mechanisms of the protective activity of the peptide against the
Ab1–42-induced learning and memory impairment. Note should be
made that a relatively small difference occurred among groups in
the MWM, which might be attributable to the AD model based on
intracerebroventricular infusion of Ab or/and the inadequate
sample size in this study. Further, the effect of the special peptide
on cognitive function should be confirmed using AD transgenic
mice, such as the 5xFADAD model mice [21].
In summary, by using phage display technology, we successfully
identified a 12-amino acid peptide that can specifically bind to
Ab1-10. Such a peptide may not only serve to inhibit the
aggregation of Ab into plaques, but also inhibit the toxic effects
of Ab. Therefore, the special peptide may be a potential drug for
the treatment of AD.
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